ECSP099538A - Un compuesto de [1,2,3]benzotriazinona sustituidos en la posición 3 para mejorar las respuestas sinápticas glutamatérgicas - Google Patents
Un compuesto de [1,2,3]benzotriazinona sustituidos en la posición 3 para mejorar las respuestas sinápticas glutamatérgicasInfo
- Publication number
- ECSP099538A ECSP099538A EC2009009538A ECSP099538A ECSP099538A EC SP099538 A ECSP099538 A EC SP099538A EC 2009009538 A EC2009009538 A EC 2009009538A EC SP099538 A ECSP099538 A EC SP099538A EC SP099538 A ECSP099538 A EC SP099538A
- Authority
- EC
- Ecuador
- Prior art keywords
- compounds
- present
- synaptic responses
- improve
- benzotriazinona
- Prior art date
Links
- 239000002131 composite material Substances 0.000 title 1
- 230000000946 synaptic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 102000003678 AMPA Receptors Human genes 0.000 abstract 2
- 108090000078 AMPA Receptors Proteins 0.000 abstract 2
- 230000003931 cognitive performance Effects 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 230000000971 hippocampal effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000009782 synaptic response Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/64—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with three nitrogen atoms as the only ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención incluye, en un aspecto, un compuesto tal como el que muestra la estructura I, y que se describen en la Sección II de la siguiente Descripción Detallada. Se ha descubierto que la administración de compuestos de esta clase aumentan las respuestas sinápticas mediadas por los receptores AMPA. Los compuestos de la presente invención son significativamente e inesperadamente más potentes que los compuestos descriptos anteriormente para aumentar la función del receptor AMPA en cultivos neuronales primarios y en rodajas de hipocampo de rata y para mejorar el desempeño cognitivo, tal como el desempeño en las tareas de igualación demorada de la muestra. Esta actividad inesperada se traduce en los compuestos farmacéuticos y los correspondientes métodos de uso, incluyendo los métodos de tratamiento que utilizan concentraciones significativamente menores (sobre una base de mol a mol) de los presente compuestos comparado con las composiciones de la técnica previa.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87862607P | 2007-01-03 | 2007-01-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP099538A true ECSP099538A (es) | 2009-12-28 |
Family
ID=39608955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2009009538A ECSP099538A (es) | 2007-01-03 | 2009-07-23 | Un compuesto de [1,2,3]benzotriazinona sustituidos en la posición 3 para mejorar las respuestas sinápticas glutamatérgicas |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20100041647A1 (es) |
| EP (1) | EP2114158B1 (es) |
| JP (1) | JP2010514837A (es) |
| KR (1) | KR20090098999A (es) |
| CN (1) | CN101626686A (es) |
| AP (1) | AP2009004915A0 (es) |
| AR (1) | AR064739A1 (es) |
| AU (1) | AU2007342364A1 (es) |
| BR (1) | BRPI0720323A2 (es) |
| CA (1) | CA2674321A1 (es) |
| CO (1) | CO6210740A2 (es) |
| CR (1) | CR10913A (es) |
| EA (1) | EA200900937A1 (es) |
| EC (1) | ECSP099538A (es) |
| IL (1) | IL199662A0 (es) |
| MA (1) | MA31159B1 (es) |
| MX (1) | MX2009007209A (es) |
| NZ (1) | NZ578290A (es) |
| TN (1) | TN2009000278A1 (es) |
| WO (1) | WO2008085505A1 (es) |
| ZA (1) | ZA200905065B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY154877A (en) | 2007-01-03 | 2015-08-14 | Servier Lab | 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamateric synaptic responses |
| EA200901546A1 (ru) | 2007-05-17 | 2010-04-30 | Кортекс Фармасеутикалс, Инк. | Дизамещенные амиды для усиления глутаматергических синаптических ответов |
| US8119632B2 (en) | 2007-08-10 | 2012-02-21 | Cortex Pharmaceuticals, Inc. | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses |
| BRPI0814149A2 (pt) | 2007-08-10 | 2011-09-13 | Cortex Pharma Inc | composto, composição farmacêutica, métodos de tratamento e uso do composto |
| CN101801939A (zh) * | 2007-09-20 | 2010-08-11 | 科泰克斯药品公司 | 用于增强谷氨酸能突触反应的3-取代1,2,3-三嗪-4-酮类和3-取代1,3-嘧啶酮类 |
| US20110257186A1 (en) | 2010-04-15 | 2011-10-20 | Staubli Ursula V | Compositions and methods for treating visual disorders |
| EP2948135B1 (en) | 2013-01-25 | 2019-01-02 | Case Western Reserve University | Compositions and methods for the treatment of pervasive development disorders |
| CN105418525B (zh) * | 2015-12-16 | 2017-12-15 | 郑州轻工业学院 | 一种n‑取代1,2,3‑苯并三嗪‑4‑酮的制备方法 |
| CN114716416B (zh) * | 2022-04-11 | 2023-06-16 | 湖北大学 | 3,4-二氢吡咯衍生物及其一锅法合成 |
| AU2024240637A1 (en) * | 2023-03-21 | 2025-09-18 | Vivozon,Inc. | Double regulator for mglur5 and hdac6 and use thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3723436A (en) * | 1971-02-25 | 1973-03-27 | Sun Oil Co | Process for aromatic lactams |
| FR2597103B1 (fr) * | 1986-04-15 | 1988-12-16 | Provesan Sa | Procede de preparation de derives d'oxazinobenzothiazine 6,6-dioxyde |
| GB9202915D0 (en) * | 1992-02-12 | 1992-03-25 | Wellcome Found | Chemical compounds |
| EP1156043B1 (en) * | 1992-07-24 | 2003-11-12 | The Regents Of The University Of California | Drugs that enhance synaptic responses mediated by ampa receptors |
| US5962477A (en) * | 1994-04-12 | 1999-10-05 | Adolor Corporation | Screening methods for cytokine inhibitors |
| US5650409A (en) * | 1995-06-02 | 1997-07-22 | Cortex Pharmaceuticals, Inc. | Benzoyl piperidines/pyrrolidines for enhancing synaptic response |
| US5736543A (en) * | 1996-04-03 | 1998-04-07 | The Regents Of The University Of California | Benzoxazines for enhancing synaptic response |
| AU4416197A (en) * | 1996-09-17 | 1998-04-14 | Regents Of The University Of California, The | Positive ampa receptor modulation to enhance brain neurotrophic factor expression |
| US6110935A (en) * | 1997-02-13 | 2000-08-29 | The Regents Of The University Of California | Benzofurazan compounds for enhancing glutamatergic synaptic responses |
| US5985871A (en) * | 1997-12-24 | 1999-11-16 | Cortex Pharmaceuticals, Inc. | Benzoxazine compounds for enhancing synaptic response |
| US6713474B2 (en) * | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| US6303542B1 (en) * | 2000-08-18 | 2001-10-16 | Rohm And Haas Company | Herbicidal 3-substituted-phenyl-1,2,3-benzotriazin-4-ones |
| PL371722A1 (en) * | 2001-11-26 | 2005-06-27 | Cortex Pharmaceuticals, Inc. | Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses |
| AUPS255202A0 (en) * | 2002-05-27 | 2002-06-13 | Monash University | Agents and methods for the treatment of disorders associated with motor neuron degeneration |
| DE10238865A1 (de) * | 2002-08-24 | 2004-03-11 | Boehringer Ingelheim International Gmbh | Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| GB0317482D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
| CN1897950A (zh) * | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| MY154877A (en) * | 2007-01-03 | 2015-08-14 | Servier Lab | 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamateric synaptic responses |
| EA200901546A1 (ru) * | 2007-05-17 | 2010-04-30 | Кортекс Фармасеутикалс, Инк. | Дизамещенные амиды для усиления глутаматергических синаптических ответов |
| CN101801939A (zh) * | 2007-09-20 | 2010-08-11 | 科泰克斯药品公司 | 用于增强谷氨酸能突触反应的3-取代1,2,3-三嗪-4-酮类和3-取代1,3-嘧啶酮类 |
-
2007
- 2007-12-28 AU AU2007342364A patent/AU2007342364A1/en not_active Abandoned
- 2007-12-28 MX MX2009007209A patent/MX2009007209A/es not_active Application Discontinuation
- 2007-12-28 BR BRPI0720323A patent/BRPI0720323A2/pt not_active IP Right Cessation
- 2007-12-28 AP AP2009004915A patent/AP2009004915A0/xx unknown
- 2007-12-28 EA EA200900937A patent/EA200900937A1/ru unknown
- 2007-12-28 KR KR1020097015941A patent/KR20090098999A/ko not_active Ceased
- 2007-12-28 US US12/448,770 patent/US20100041647A1/en not_active Abandoned
- 2007-12-28 CA CA002674321A patent/CA2674321A1/en not_active Abandoned
- 2007-12-28 NZ NZ578290A patent/NZ578290A/en not_active IP Right Cessation
- 2007-12-28 JP JP2009544856A patent/JP2010514837A/ja active Pending
- 2007-12-28 EP EP07868092A patent/EP2114158B1/en active Active
- 2007-12-28 WO PCT/US2007/026415 patent/WO2008085505A1/en not_active Ceased
- 2007-12-28 CN CN200780051958A patent/CN101626686A/zh active Pending
-
2008
- 2008-01-03 AR ARP080100021A patent/AR064739A1/es not_active Application Discontinuation
-
2009
- 2009-06-30 TN TNP2009000278A patent/TN2009000278A1/fr unknown
- 2009-07-02 IL IL199662A patent/IL199662A0/en unknown
- 2009-07-03 CR CR10913A patent/CR10913A/es not_active Application Discontinuation
- 2009-07-14 CO CO09072923A patent/CO6210740A2/es not_active Application Discontinuation
- 2009-07-20 ZA ZA200905065A patent/ZA200905065B/xx unknown
- 2009-07-23 EC EC2009009538A patent/ECSP099538A/es unknown
- 2009-07-31 MA MA32133A patent/MA31159B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AP2009004915A0 (en) | 2009-08-31 |
| EP2114158A1 (en) | 2009-11-11 |
| TN2009000278A1 (en) | 2010-10-18 |
| AR064739A1 (es) | 2009-04-22 |
| MX2009007209A (es) | 2009-10-12 |
| CO6210740A2 (es) | 2010-10-20 |
| WO2008085505A1 (en) | 2008-07-17 |
| BRPI0720323A2 (pt) | 2016-08-09 |
| AU2007342364A1 (en) | 2008-07-17 |
| CN101626686A (zh) | 2010-01-13 |
| CA2674321A1 (en) | 2008-07-17 |
| EP2114158A4 (en) | 2010-05-05 |
| ZA200905065B (en) | 2010-04-28 |
| US20100041647A1 (en) | 2010-02-18 |
| MA31159B1 (fr) | 2010-02-01 |
| KR20090098999A (ko) | 2009-09-18 |
| EP2114158B1 (en) | 2012-08-08 |
| NZ578290A (en) | 2012-03-30 |
| EA200900937A1 (ru) | 2009-12-30 |
| CR10913A (es) | 2009-09-21 |
| IL199662A0 (en) | 2010-04-15 |
| JP2010514837A (ja) | 2010-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20110233A (es) | Nuevos compuestos halosustituidos | |
| HN2008000646A (es) | Antagonistas de los receptores 2 de dopamina de rapida disociacion | |
| CR9786A (es) | Compuestos de bencimidazol-tiofeno | |
| CL2007001887A1 (es) | Compuestos derivados de bifensustuidas por tetrazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades asociadas con los receptores purinergicos de p2x, tales como trastornos gastrointes | |
| UY29004A1 (es) | Compuestos derivados sustituídos de ácidos, glicina y alanina; procedimiento para su preparación y uso. | |
| PA8796201A1 (es) | Agentes anti-infecciosos y su uso | |
| ECSP10010695A (es) | Compuestos de piridina | |
| NI200800217A (es) | Arildihidroisoquinolinonas sustituidas con azaciclilo, procedimiento para su preparación y su uso como medicamentos. | |
| ECSP11011348A (es) | 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3 | |
| UY32926A (es) | Compuestos como antagonistas de los receptores de ácido lisofosfatídico | |
| CR8266A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| SV2010003662A (es) | Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081 | |
| NI201100208A (es) | Pirazinilpirazoles | |
| CR10497A (es) | Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38 | |
| UY32443A (es) | Nuevos tetrahidronaftalenos, procesos para su preparación y uso de los mismos como medicamento. | |
| PE20141155A1 (es) | Analogos del acido epoxi-eicosatrienoico y metodos para hacer y de uso del mismo | |
| UY29223A1 (es) | Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación | |
| ECSP11011346A (es) | 3-Amino-2-mercaptoquinolina sustituida como modulador de KCNQ2/3 | |
| ECSP11011345A (es) | 2-mercapto-3-aminopiridina sustituida como moduladores de kcnq2/3 | |
| PA8574701A1 (es) | Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen | |
| GT200600144A (es) | 1h-quinazolin-2,4-dionas | |
| NI201100015A (es) | Compuestos novedosos activos como antagonistas de receptor muscarínico. | |
| CO6280503A2 (es) | Conjugados de neurturina novedosas para uso farmaceutico | |
| DOP2006000017A (es) | Pirazolopiridinas y sales de las mismas, una composición farmaceútica que comprende dichos compuestos, un método para prepararlos y su uso | |
| UY31288A1 (es) | Nuevos tetrahidronaftalenos sustituidos, procedimiento para su preparacion y uso de los mismos como medicamentos |